BridgeMD
Evaluation of Allergen Specific Vaccination of Dog Allergic Patients in Swedish Practice
EU CTIS ID: 2024-517649-15-00
What this study is testing
The primary objective of this trial is to evaluate the effectiveness of Alutard SQ dog in dog allergic patients by evaluating improvement in allergic symptoms after one year treatment
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- The subject has given their written consent to participate in the trial.
- Age between 18-50
- Moderate to severe allergy symptoms when in contact with dogs.
- Considered suitable by investigator to be prescribed Alutard SQ Dog in line with approved SPC.
- For female subjects of fertile age, adequate contraception should be used. A negative pregnancy test should be collected prior to inclusion.
- Allergy confirmed with positive specific IgE to dog.
You likely can't join if
- Pregnancy or nursing.
- Any condition, as judged by the investigator, which might make follow-up or investigations inappropriate.
- Any patient that according to the Declaration of Helsinki is unsuitable for enrollment.
- Autoimmune or collagen disease.
- Cardiovascular disease.
- Hepatic disease.
See the full eligibility criteria
- The subject has given their written consent to participate in the trial.
- Age between 18-50
- Moderate to severe allergy symptoms when in contact with dogs.
- Considered suitable by investigator to be prescribed Alutard SQ Dog in line with approved SPC.
- For female subjects of fertile age, adequate contraception should be used. A negative pregnancy test should be collected prior to inclusion.
- Allergy confirmed with positive specific IgE to dog.
- Pregnancy or nursing.
- Any condition, as judged by the investigator, which might make follow-up or investigations inappropriate.
- Any patient that according to the Declaration of Helsinki is unsuitable for enrollment.
- Autoimmune or collagen disease.
- Cardiovascular disease.
- Hepatic disease.
- Renal disease.
- Cancer.
- Upper airway disease (non-allergic sinusitis, nasal polyposis, chronic obstructive and restrictive lung disease).
- Medication with a possible side-effect of interfering with the immune response.
- Previous immuno- or chemotherapy.
- Chronic disease.
- Withdrawal of consent.
- Discontinuation of the study treatment as defined in section 7.1.
- Premature withdrawal by the Investigator/Sponsor due to safety or any other reason.
- Lack of adherence to the study protocol and instructions given by the investigator.
- Major metabolic disease.
- Alcohol or drug abuse.
- Mental incapability of coping with the study.
- Known or suspected allergy to the study product.
- Suspicion of or confirmed bacterial infection.
- Mite allergy.
- Dog owner.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.